Capsule Summary Slidesets

Share

Program Content

Activities

  • Ifinatamab Deruxtecan in SCLC
    Subgroup Analysis of Patients With Refractory SCLC From a Phase I/II Trial Evaluating the Novel ADC Ifinatamab Deruxtecan
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 13, 2023

    View Activity
  • Phase Ib FAVOUR Trial
    FAVOUR: Phase Ib Study of Furmonertinib in EGFR Exon 20 Insertion–Positive Locally Advanced or Metastatic NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2023

    View Activity
  • HERTHENA-Lung01
    HERTHENA-Lung01: Phase II Trial of Patritumab Deruxtecan in Previously Treated EGFR-Mutated Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2023

    View Activity
  • DESTINY-Lung02
    DESTINY-Lung02: Phase II Trial of Trastuzumab Deruxtecan in Patients With Previously Treated HER2-Mutated Metastatic NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2023

    View Activity
  • LUNAR Subgroup Analysis
    Tumor Treating Fields + Immune Checkpoint Inhibition in Metastatic NSCLC After Platinum Failure: Phase III LUNAR Subgroup Analysis by PD-L1 Expression
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2023

    View Activity
  • FLAURA2: Osi ± CT in EGFR+ NSCLC
    FLAURA2: Phase III Trial of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 14, 2023

    View Activity
  • Phase I/II TRIDENT-1 Update
    TRIDENT-1 Update: Phase I/II Study of Repotrectinib in Patients With ROS1 Fusion–Positive Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2023

    View Activity
  • AEGEAN Surgical Outcomes
    Phase III AEGEAN: Analysis of Surgery-Related Outcomes With Neoadjuvant Durvalumab + CT Followed by Adjuvant Durvalumab in Resectable NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 15, 2023

    View Activity
  • 1L Cemiplimab in Adv NSCLC With Liver Mets
    Phase III EMPOWER-Lung 1 and 3: Updated Long-term Subgroup Analysis of Cemiplimab in Newly Diagnosed Advanced NSCLC With Liver Metastases
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 19, 2023

    View Activity
  • Phase Ib TROPION-Lung04
    Phase Ib TROPION-Lung04: Datopotamab Deruxtecan + Durvalumab ± Carboplatin in Advanced/Metastatic NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2023

    View Activity
  • Amivantamab in METex14+ NSCLC
    Phase I CHRYSALIS Update: Amivantamab in Expanded Cohort of Patients With Advanced NSCLC and MET Exon 14 Skipping Mutations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2023

    View Activity
  • Phase II I-SABR
    Phase II I-SABR: Stereotactic Ablative Radiotherapy ± Nivolumab for Untreated Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2023

    View Activity
  • INSIGHT 2 Primary Analysis
    Phase II INSIGHT 2: Primary Analysis of Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2023

    View Activity
  • Phase II EVOKE-02
    Phase II EVOKE-02: First-line Sacituzumab Govitecan + Pembrolizumab in Metastatic NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 20, 2023

    View Activity

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc